A 67-year-old male had a new total prostate-specific antigen (PSA) level of 5.37 ng/mL, which on repeat testing about a month later was 0.99 ng/mL; why would the PSA drop so dramatically, and could the first result have been an error?

PSA Fluctuation: Laboratory Error vs. Biological Variation

The dramatic drop in PSA from 5.37 to 0.99 ng/mL over one month most likely represents biological variability rather than laboratory error, and you should repeat the PSA test before making any clinical decisions. 1

Understanding PSA Variability

PSA levels demonstrate significant short-term fluctuation even without any intervention:

• Natural variation is common and substantial: In men with initial PSA elevations, approximately 44% will have a normal PSA on repeat testing within weeks to months, and this occurs even in men who ultimately have prostate cancer 2
• One-third of patients show differences >1.0 ng/mL between measurements taken within 90 days, with documented variations ranging from -5.3 to +7.5 ng/mL 3
• Any detectable PSA following initial measurement should be repeated for confirmation to eliminate laboratory error 1

Clinical Significance of PSA Decrease

The magnitude of decrease in this case (approximately 81% reduction) has important implications:

• A ≥20% decrease in PSA significantly reduces cancer risk: Men with this degree of PSA reduction have lower odds of prostate cancer (OR 0.37) and particularly high-grade disease (OR 0.13) 4
• However, PSA decreases do not exclude cancer: 43% of men ultimately diagnosed with prostate cancer, including those with high-grade disease, show short-term PSA decreases below their baseline 5
• When PSA returns to <4.0 ng/mL on repeat testing, the risk of both prostate cancer and high-grade disease is substantially reduced (OR 0.33 and 0.01, respectively) 6

Recommended Approach

Obtain a third PSA measurement to establish a reliable baseline:

• Wait at least 48 hours after ejaculation before testing, as results are more reliable with abstinence 1
• Consider potential confounding factors: recent prostatitis, urinary tract infection, or prostate manipulation 3
• If the patient is on finasteride or dutasteride, failure to have approximately 50% PSA decrease or any increase while on medication can indicate increased cancer risk 1

Decision Algorithm Based on Third PSA Result

If PSA remains <4.0 ng/mL:

• Continue annual monitoring with DRE and PSA 1
• Consider PSA velocity if multiple values available over 18-24 months (threshold 0.35 ng/mL/year for PSA <4.0) 1

If PSA returns to 4.0-10.0 ng/mL range:

• Consider free PSA testing: >25% suggests lower risk, <10% warrants biopsy 1
• Evaluate PSA velocity (threshold 0.75 ng/mL/year in this range) 1
• Factor in age, family history, ethnicity, and DRE findings before biopsy decision 1

If PSA returns to >5.0 ng/mL:

• Proceed with urologic evaluation and likely prostate biopsy 1

Common Pitfalls to Avoid

• Do not dismiss the initial elevated PSA as definitively erroneous without confirmation testing, as biological variation is more common than laboratory error 3, 2
• Do not assume a decreased PSA excludes cancer, as nearly half of men with prostate cancer demonstrate PSA decreases on repeat testing 5
• Do not rely on a single PSA measurement for clinical decision-making given the substantial test-to-test variability 2
• Avoid using isolated PSA values without considering the clinical context, including DRE findings, age-specific reference ranges, and patient risk factors 1